(R)-3-甲基 3,4-二氢异喹啉盐酸盐 | 14123-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢异喹啉
• 中文名称: (R)-3-甲基 3,4-二氢异喹啉盐酸盐
• 中文别名: (R)-3-甲基3,4-二氢异喹啉盐酸盐
• 英文名称: 3-methyl-3,4-dihydroisoquinoline
• 英文别名: 3-Methyl-3,4-dihydro-isochinolin
• CAS: 14123-78-5
• 化学式: C₁₀H₁₁N
• 分子量: 145.204
• InChiKey: JATHXJMZMGXQFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  (R)-3-甲基 3,4-二氢异喹啉盐酸盐 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以82.3%的产率得到3-甲基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  Conformational Analysis. 50. C-Methyl-1,2,3,4-tetrahydroisoquinolines

  摘要：

  Conformational equilibria in 1-, 3-, and 4-methyl-1,2,3,4-tetrahydroisoquinolines (THIQs) and the diastereomeric pairs of their 1,3- and 1,4-dimethyl homologs have been determined by measurement of H-3/H-4(trans) coupling constants and have been confirmed by molecular mechanics [MMP2(85]) calculations. The experimental -Delta G degrees values (a --> e) for the monomethyl compounds (computed values in parentheses) in kcal mol(-1) are Me-1, 0.56 (0.46); Me-3, 1.63 (1.53); and Me-4, -0.32 (-0.22). Agreement of experimental and calculated values is very goad as is the additivity of values for the dimethyl compounds (Table 1). Values for the corresponding hydrochlorides are Me-1, 0.19 (-0.34); Me-3, 1.15 (1.46); and Me-4, 0.35 (0.10) kcal mol(-1). The less than satisfactory agreement of experimental with computed data here is probably due to neglect of solvation. The very small or negative Delta G degrees values for Me-1 and Me-4 were ascribed not only to the pseudoaxial (rather than axial) nature of Me(ax) and the absence of a syn-axial hydrogen on the side of the benzene ring but also to a peri interaction with H(8) and H(5), respectively, destabilizing equatorial methyl at positions 1 and 4. This was confirmed by comparing computed conformational energy values with values at corresponding positions in Delta(3,4)-tetrahydropyridines (THPs). While Delta G degrees in the two series is the same for Me-3 (THIQ numbering), that for Me-1 and Me-4 is considerably smaller in the THIQ than in the THP series which latter is devoid of peri hydrogens.

  DOI：

  10.1021/jo971257r
• 作为产物：
  描述：

  非那明 在 PPA 、 Polyphosphoric acid (PPA) 作用下， 反应 9.0h， 生成 (R)-3-甲基 3,4-二氢异喹啉盐酸盐
  参考文献：
  名称：

  Synthesis and antihypertensive activity of a series of spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one]s

  摘要：

  The 2R*,11bS* and 2S*,11bS* diastereoisomers of the spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2, 5'-oxazolidin-2'-one] system were prepared by stereoselective methods. Evaluation of these compounds for antihypertensive activity by oral administration to the spontaneously hypertensive rat showed the 2S*,11bS* series was the more potent. Within that series it was found that small alkyl substituents at positions 3 and 4' enhanced antihypertensive activity and that methoxyl substitution at positions 9 and 10 was optimal. (2S,3S,11bS)-Spiro-[2-ethyl-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one] [(-)-9e] was one of the most efficacious compounds of this series, while its antipode, (+)-9e, was inactive. Selected compounds in this series were shown to be alpha-adrenoceptor antagonists.

  DOI：

  10.1021/jm00364a013

文献信息

• [EN] PROCESS FOR PRODUCING DIHYDROISOQUINOLINE ZWITTERIONS<br/>[FR] PROCEDE DE PRODUCTION DE ZWITTERIONS DE DIHYDROISOQUINOLINE
  申请人：PROCTER & GAMBLE

  公开号：WO2005047264A1

  公开（公告）日：2005-05-26

  This invention relates to a preparation of zwitterionic sulfates of substituted or unsubstituted 3, 4-dihydroisoquinoline.

  这项发明涉及制备取代或未取代3,4-二氢异喹啉的带电离子硫酸盐。
• [EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE TYPE QUINOLIZIDINONE
  申请人：MERCK & CO INC

  公开号：WO2009094279A1

  公开（公告）日：2009-07-30

  The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及化合物(I)的公式，这些化合物是M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗由M1受体介导的疾病中的用途。
• Amidine and isothiourea derivatives, compositions containing them and
  申请人：Astra Aktiebolag

  公开号：US05929085A1

  公开（公告）日：1999-07-27

  There are provided novel compounds of formula (I) ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy.

  提供了化合物的新颖化合物，其化学式为（I）##STR1## 其中X、R.sup.1、R.sup.2、R.sup.3、R.sup.4和R.sup.5如规范中定义的那样，以及它们的光学异构体和拉克酸盐，以及其制备过程、含有它们的组合物以及它们在治疗中的应用。
• Process of producing an organic catalyst
  申请人：Hiler Douglas George

  公开号：US20050113246A1

  公开（公告）日：2005-05-26

  This invention relates to a process of producing organic catalysts that may comprise iminium or oxaziridinium moieties, cleaning compositions comprising such catalysts; and methods of using such catalysts and cleaning products containing such catalysts.

  本发明涉及一种生产含有亚胺或氧杂环丙烷基团的有机催化剂的方法，以及包含这种催化剂的清洁组合物；以及使用这种催化剂和含有这种催化剂的清洁产品的方法。
• Amidine and isothiourea derivatives as inhibitors of nitric oxide
  申请人：Astra Aktiebolag

  公开号：US06140322A1

  公开（公告）日：2000-10-31

  There are provided novel compounds of formula (I) ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy.

  提供了式(I)的新化合物：##STR1## 其中X，R.sup.1，R.sup.2，R.sup.3，R.sup.4和R.sup.5如规范中所定义，以及其光学异构体和外消旋体以及其药学上可接受的盐；以及它们的制备过程，含有它们的组合物以及它们在治疗中的用途。